Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFC-1 is a specific fucoidan fraction isolated from the brown seaweed *Ascophyllum nodosum* (Iceland brown algae). It is a sulfated polysaccharide primarily composed of fucose and xylose, with a sulfate content of approximately 27.8% and sulfation occurring at the C2 and C4 positions. In preclinical research, AFC-1 has demonstrated anti-hyperlipidemic and antioxidant properties, effectively improving lipid profiles and blood glucose levels in high-fat diet-induced hyperlipidemia models. Its mechanism of action involves the modulation of lipoprotein metabolism and oxidative stress-related enzymes, as well as the preservation of gut microbiota diversity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AFC-1.